Jacobs Levy Equity Management Inc. Makes New Investment in Pyxis Oncology, Inc. (NASDAQ:PYXS)

Jacobs Levy Equity Management Inc. bought a new position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 382,840 shares of the company's stock, valued at approximately $1,405,000. Jacobs Levy Equity Management Inc. owned approximately 0.64% of Pyxis Oncology as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PYXS. Vanguard Group Inc. increased its stake in Pyxis Oncology by 7.3% in the first quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company's stock valued at $5,970,000 after purchasing an additional 94,740 shares during the last quarter. Millennium Management LLC raised its stake in shares of Pyxis Oncology by 125.3% during the 2nd quarter. Millennium Management LLC now owns 1,336,908 shares of the company's stock worth $4,425,000 after buying an additional 743,499 shares during the last quarter. Blue Owl Capital Holdings LP purchased a new stake in shares of Pyxis Oncology in the 2nd quarter worth about $3,462,000. abrdn plc increased its holdings in Pyxis Oncology by 28.9% during the 3rd quarter. abrdn plc now owns 913,045 shares of the company's stock valued at $3,351,000 after acquiring an additional 204,742 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Pyxis Oncology by 92.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 311,630 shares of the company's stock worth $1,031,000 after purchasing an additional 149,522 shares in the last quarter. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Pyxis Oncology news, CFO Pamela Ann Connealy acquired 88,850 shares of the firm's stock in a transaction that occurred on Tuesday, November 26th. The stock was acquired at an average cost of $1.96 per share, with a total value of $174,146.00. Following the acquisition, the chief financial officer now directly owns 1,199,143 shares of the company's stock, valued at $2,350,320.28. This represents a 8.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 9.80% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. William Blair cut Pyxis Oncology from an "outperform" rating to a "market perform" rating in a research report on Thursday, November 21st. HC Wainwright reissued a "buy" rating and set a $7.00 price objective on shares of Pyxis Oncology in a research note on Thursday, November 21st. Royal Bank of Canada lifted their price objective on Pyxis Oncology from $7.00 to $10.00 and gave the company an "outperform" rating in a research report on Thursday, November 21st. Finally, Stephens started coverage on shares of Pyxis Oncology in a research note on Friday, November 8th. They set an "overweight" rating and a $13.00 price objective for the company. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $10.00.

Pyxis Oncology Stock Up 7.2 %

Shares of Pyxis Oncology stock traded up $0.12 on Monday, reaching $1.79. 975,663 shares of the company were exchanged, compared to its average volume of 781,037. Pyxis Oncology, Inc. has a 1-year low of $1.64 and a 1-year high of $6.85. The company's 50-day moving average is $3.28 and its two-hundred day moving average is $3.44.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.